Peptide Tools to Study SARS-CoV-2

JPT's Peptide Tools to Study SARS-CoV-2

JPT has launched a broad development program to provide access to genome spanning SARS-CoV-2 peptide tools and its different mutation variants for applications such as:

  • SARS-CoV-2 clinical trial immune monitoring
  • SARS-CoV-2 evaluation of cross reactivities
  • SARS-CoV-2 blood and sero test development
  • SARS-CoV-2 T-and B-cell epitope discovery

We have broadened our portfolio of coronavirus related products beyond SARS-CoV-2, including SARS-CoVMERS-CoV and common cold viruses CoV 229E, OC43, HKU1 and NL63. Have a look below!


About SARS-CoV-2

SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2), the causative agent of Covid-19, is responsible for the current pandemic. Developing and monitoring vaccines, therapies and diagnostic tests that are safe, effective, and rapidly deployable is an urgent global health priority.
Check our SARS-CoV-2 Flyer

Alpha

Alpha

WHO Designation 
Variant of Concern 202012/01
Alternative names
Lineage B.1.1.7, UK variant, British variant, Kent variant, Alpha

More Information
Beta

Beta

WHO Designation
Variant of Concern
Alternative names
501Y.V2 variant, 20H/501Y.V2, 20C/501Y.V2, B.1.351 lineage, South African variant, Beta

More Information
Delta

Delta

WHO Designation
Variant of Concern
Alternative names
B.1.617.2 lineage, G/478K.V1, 20A/S:478K, Indian Variant, Delta

More Information
Epsilon

Epsilon

WHO Designation
Formerly Monitored Variant
Alternative names
B.1.429 lineage, CAL.20C, Los Angeles Variant, Epsilon

More Information
Gamma

Gamma

WHO Designation
Variant of Concern
Alternative names
P.1, B.1.1.248, B.1.1.28.1, 20J/501Y.V3, Brazil(ian) variant, Gamma

More Information
Kappa

Kappa

WHO Designation
Formerly Monitored Variant

Alternative names
B.1.617.1 lineage, G/452R.V3, Indian Variant, Kappa
More Information
Loading...

Lambda

Lambda

WHO Designation 
Variant of Interest
C.37 lineage
More Information
Omicron BA.1

Omicron BA.1

WHO Designation
Variant of Concern

B.1.1.529 lineage (BA.1)
More Information
Omicron BA.2

Omicron BA.2

WHO Designation
Variant of Concern

B.1.1.529 lineage (BA.2)
More Information
Loading...

Spike Mutations in SARS-CoV-2 Variants of Concern covered by PepMix™

see Overview Table

Peptide Tools to Study SARS-CoV-2

Cellular Immunity
-> PepMix™ Peptide Pools
  • Antigen-specific T-cell stimulation
  • Cellular immune monitoring
  • Vaccine target discovery
  • Blood test development
  • Cross reactivity testing (SARS-CoV-2 vs. SARS, MERS, HCoV 229E, OC43…)
  • Cell therapy development
  • Efficient epitope mapping and identification
  • Matrix Pools and individual peptides spanning a whole antigen in one set
  • Minimal sample amount required
  • Antigen specific T-cell stimulation in T-cell assays (i.e. ELISpot, ICS)
  • Immune monitoring
  • Proliferation assays
  • T-cell expansion
Humoral Immunity
-> PepStar™ Peptide Microarrays
  • Humoral immune monitoring
  • Antibody epitope discovery
  • Cross reactivity testing (SARS-CoV-2 vs. SARS, MERS, HCoV 229E, OC43…)
  • Seromarker discovery
PepStar™ Antigen Collection Pan-Coronavirus
for cross reactivity testing with SARS-CoV-2 vs. SARS, MERS, HCoV 229E, OC43…)
PepStar™ Peptide Microarrays
for individual SARS-CoV-2 and SARS-CoV antigens
Tailored PepStar™ Peptide Microarrays
You define content and layout, we provide economic and fast production in our regulated clean-room environment. We also offer our assay and analysis service using your samples with your tailored peptide microarray.

  • Thousands of peptides spanning the entire SARS-CoV-2 genome using smallest sample volumes
  • Incubation using smallest sample volumes
  • Study of antibody cross-reactivities between SARS-CoV-2 and other corona viruses
  • Verification of peptide binders with a large numbers of samples
  • Transfer of results to ELISA platform for rapid test development
  • Peptide ELISA development and service using SARS-CoV-2 peptides or a combination with other corona viruses
  • ELISA-based validation service of peptide binders identified by using JPT’s peptide microarray platform
  • Collaborative ELISA test development
Clinical Immune Monitoring & Cell Therapy
-> Clinical Grade Peptides & PepMix™ Peptide Pools
  • High quality chemically synthesized antigen source for vaccine trial monitoring
  • Ancillary reagents for cellular therapy development
  • Full analytical coverage, stability testing, batch documentation and more
Proteomics
-> SpikeMix™ SARS-CoV-2
  • Identify SARS CoV-2 antigens from biological samples
  • Mass spectrometry based assays (MRM)
  • Screen 23 proteotypic peptides from SARS-CoV-2
Loading...

References

References

  • Functional Analysis of Human and Feline Coronavirus Cross-Reactive Antibodies Directed Against the SARS-CoV-2 Fusion Peptide
    Vanderheijden et al., Frontiers in Immunology (2022) - PMID: 35069571
  • Durable immunogenicity, adaptation to emerging variants and low dose efficacy of AAV-based COVID19 platform in macaques
    Zabaleta et al., Molecular Therapy (2022)
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
  • Enhanced Humoral Immune Response After COVID-19 Vaccination in Elderly Kidney Transplant Recipients on Everolimus Versus Mycophenolate Mofetil–containing Immunosuppressive Regimens
    de Boer et al., Translantation (2022) - PMID: 35546527
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
  • SARS-CoV2 wild type and mutant specific humoral and T cell immunity is superior after vaccination than after natural infection
    Richardson et al., PLoS One (2022) - PMID: 35468147
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.1.7 / Alpha), SARS-CoV-2 (Spike B.1.351 / Beta), SARS-CoV-2 (Spike P.1 / Gamma), SARS-CoV-2 (Spike B.1.617.2 / Delta)
  • Two DNA vaccines protect against severe disease and pathology due to SARS-CoV-2 in Syrian hamsters
    Babuadze et al., NPJ Vaccines (2022) - PMID: 35474311
    Product used: PepMix™ SARS-CoV (Spike Glycoprotein)
  • Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2 Specific T cell therapy products
    Durkee-Shock et al., Molecular Therapy: Methods & Clinical Development (2022)
  • Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
    Cabeza et al., Neurology: Neuroimmunology & Neuroinflammation - PMID: 35523569
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
  • Children and Adults With Mild COVID-19: Dynamics of the Memory T Cell Response up to 10 Months
    Kaaijk et al., Frontiers in Immunology (2022)
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), HCoV-OC43 (Spike Glycoprotein)
  • Strong peak immunogenicity but rapid antibody waning following third vaccine dose in elderly residents of care homes
    Tut et al., Research Square (2022)
    Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
  • Discordant antibody and T cell responses to the SARS-CoV-2 Omicron variant in COVID-19 mRNA vaccine recipient
    Woldemeskel et al., Clinical Infectious Diseases (2022) - PMID: 35438751
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (S-RBD B.1.1.529 / Omicron)
  • USA SARS-CoV-2 Epsilon Variant: Though Highly Transmissible has an Adjusted Muted Host T-Cell Response
    Plummer et al., Clinical Infectious Diseases (2022) - PMID: 35438777
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (Spike B.1.429 / Epsilon)
  • mRNA booster vaccination protects extremely aged mice against the SARS-CoV-2 Omicron variant
    Dowling et al., Research Square (2022)
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (S-RBD B.1.1.529 / Omicron)
  • Viral Evolution and Immunology of SARS-CoV-2 in a Persistent Infection after Treatment with Rituximab
    van der Moerden et al., Viruses (2022)
  • Dynamics of SARS-CoV-2-Spike-reactive antibody and T-cell responses in chronic kidney disease patients within three months after COVID-19 full vaccination
    Panizo et al., Clinical Kidney Journal (2022)
    Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
  • Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): a single blind, randomized, non-inferiority trial
    Pannus et al., MedRxiv (2022)
  • Temporal changes in T cell subsets and expansion of cytotoxic CD4+ T cells in the lungs in severe COVID-19
    Kaneko et al., Clinical Immunology (2022) - PMID: 35364330
  • T cell response against SARS-CoV-2 persists after one year in patients surviving severe COVID-19
    Venet et al., EBioMedicine (2022) - PMID: 35349827
  • CD4+ T Cell Dysfunction in Severe COVID-19 Disease is TNFalpha/TNFRI-Dependent
    Popescu et al., American Journal of Respiratory Critical Care Medicine - PMID: 35348444
  • The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors
    Kroemer et al., Front Public Health (2022) - PMID: 35372242
  • High antibody and reduced cellular response in children up to one year after SARS-CoV-2 infection
    Jacobsen et al., Research Square (2022)
  • Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study
    Lim et al., Nature Cancer (2022) - PMID : 35332334
  • Self-amplifying mRNA SARS-CoV-2 vaccines raise cross-reactive immune response to variants and prevent infection in animal models
    Palladino et al., Methods and Clinical Development (2022)
  • Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine
    Gallais et al., Frontiers in Immunology (2022) - PMID: 35281046
  • SARS‐CoV‐2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease
    Duengelhoef et al., United European Gastroenterol Journal (2022) - PMID: 35289983
  • Novel T cell interferon gamma release assay (IGRA) using spike recombinant protein for COVID19 vaccine response and Nucleocapsid for SARS-Cov2 response
    Renaudineau et al., Clinical Immunology (2022) - PMID: n.a.
  • Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination
    Sheng et al., Journal of the Formosan Medical Association (2022) - PMID: 35305895
  • Modular capsid decoration boosts adenovirus vaccine-induced humoral and cellular immunity against SARS-CoV-2
    Dicks et al., BioRxiv (2022)
  • SARS-CoV- 2 (COVID- 19)-specific T cell and B cell responses in convalescent rheumatoid arthritis: Monozygotic twins pair case observation
    Arruda et al., Immunology (2022) - PMID: 35212005
    Products used: PepMix™ SARS-CoV-2 (NCAP) & SARS-CoV-2 (Spike Glycoprotein)
  • Humoral and Cellular Immune Responses of Solid Organ Transplant Patients on Belatacept to Three Doses of mRNA-Based Anti-SARS-CoV-2 Vaccine
    Abravanel et al., Vaccines (2022)
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
  • Three-month follow-up of heterologous vs homologous third vaccination in kidney transplant recipients
    Heinzel et al., MedRxiv (2022)
  • Performance comparison of a fow cytometry immunoassay for intracellular cytokine staining and the QuantiFERON® SARS-CoV-2test for detection and quantifcation of SARS-CoV-2-Spike-reactiveIFN-γ-producing T cells after COVID-19 vaccination
    Tormo et al., European Journal of Clinical Microbiology & Infectious Diseases (2022) - PMID: 35165804
  • SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variant
    Panikkar et al., Pathogens (2022) - PMID: 35157735
  • T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all prior infected and vaccinated individuals
    Vivek Naranbhai et al., MedRxiv (2022) - PMID: 35018386
  • Innate and adaptive immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA vaccine response in elderly people
    Joana Vitallé et al., medRxiv (2022) - PMID: n.a.
  • Temporary hold of mycophenolate boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients
    Eva Schrezenmeier et al., MedRxiv (2022) 
  • Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents
    Nina Koerber et al., Nature Communications (2022)
  • Persistent T-Cell Reactivity in a Seronegative Patient after SARS-CoV-2 Infection and One Vaccination
    Nico Andreas et al., Vaccines (2022)
  • Development of an effective immune response in adults with Down Syndrome 2 after SARS-CoV-2 vaccination
    Laura Esparcia-Pinedo et al., MedRxiv (2022) 
  • Antibody and T cell responses to SARS-CoV-2 mRNA vaccines during maintenance therapy for immune-mediated inflammatory diseases
    Dayam et al., MedRxiv (2022)
  • Infection or a third dose of mRNA vaccine elicit neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients
    Charmetant et al., Science Translational Medicine (2022) - PMID: 35103481
  • Concordance of B and T cell responses to SARS-CoV-2 infection, irrespective of symptoms suggestive of COVID-19
    Österdahl et al., MedRxiv (2022) 
  • Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice
    Lázaro-Frías et al., Vaccines (2022)
  • mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron
    Gagne et al., BioRxiv (2022)
  • Effectiveness and durability of the mRNA vaccine-induced SARSCoV-2-specific humoral and cellular immunity in severe asthma patients on biological therapy
    Prodrazil et al., MedRxiv (2022)
  • Limited Recognition of Highly Conserved Regions of SARS-CoV-2
    Swaminathan et al., Microbiology Spectrum (2022) - PMID: 35196796
  • Assessment of humora land cellular immune responses to SARSCoV-2 vaccination (BNT162b2) inimmunocompromised renal allograft recipients
    Zhang et al., Transplant Infectious Diseases (2022)
  • Tacrolimus-resistant SARS-CoV-2-specific T-cell products to prevent and treat severe COVID-19 in immunosuppressed patients
    Peter et al., Molecular Therapy (2022)
  • BNT162b2 Vaccine Induces Neutralizing Antibodies and Poly-Specific T Cells in Humans
    Ugur Sahin et al., Nature (2021)
  • Cross-Reactive CD4+ T Cells Enhance SARS-CoV-2 Immune Responses Upon Infection and Vaccination
    Loyal et al, Science (2021)
  • Protection Against SARS-CoV-2 Beta Variant in mRNA-1273 Vaccine–Boosted Nonhuman Primates
    Kizzmekia S. Corbett et al., Science, (2021)
  • Children Develop Strong and Sustained Cross-Reactive Immune Responses Against Spike Protein Following SARS-CoV-2 Infection, With Enhanced Recognition of Variants of Concern
    Alexander C. Dowell et.al., medRxiv (2021)
  • Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2
    Krystle K.Q. Yu et.al., JCI Insight (2021) - PMID: 33621211
  • Targeting SARS-CoV-2 Receptor-Binding Domain to Cells Expressing CD40 Improves Protection to Infection in Convalescent Macaques
    Romain Marlin et.al., Nature Communications (2021)
  • Longitudinal Analysis of Human Memory T-Cell Response according to the Severity of Illness up to 8 Months after SARS-CoV-2 Infection
    Chang Kyung Kang et.al., The Journal of Infectious Diseases (2021) - PMID: 33755725
  • Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection
    Jianmin Zuo et.al., Nature (2021) - PMID: 33674800
  • SARS-CoV-2 Spike Protein Arrested In The Closed State Induces Potent Neutralizing Responses
    George W. Carnell et.al., bioRxiv (2021)
  • First Report Demonstrating The Safety And Immunogenicity Of The SARS-COV-2 BNT162b1 mRNA Vaccine In Younger And Older Chinese Adults: A Randomized, Placebo-Controlled, Observer-Blind Phase I Study
    Fengcai Zhu et.al., Research Square (2021)
  • Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With Belatacept
    Nathalie Chavator et al., Transplantation, (2021)
  • SARS-CoV-2 Specific Memory T Cell Epitopes Identified in COVID-19-Recovered Subjects
    Juan Zhao et al., Virus Res, (2021)
  • SARS-CoV2 Mutant-Specific T Cells and Neutralizing Antibodies After Vaccination and up to 1 Year After Infection
    Richardson, J.R. et al., ISAR Bioscience, (2021)
  • COVID-19 Subunit Vaccine with a Combination of TLR1/2 and TLR3 Agonists Induces Robust and Protective Immunity
    Soo-Kyung Jeong et al., Vaccines, (2021)
  • Impairment of CD4+ T and Memory B Cell Responses but Normal Memory CD8+T-Cell Activation on Crohn’s Disease after COVID-19 Vaccination: A Twin Case
    Fabiana Gil-Melgaço et al., Viruses, (2021)
  • Weak Immunogenicity of SARS-CoV-2 Vaccine in Patients With Hematologic Malignancies
    Florent Malard et al., Blood Cancer J, (2021)
  • CD4+ T Cells of Prostate Cancer Patients Have Decreased Immune Responses to Antigens Derived From SARS-CoV-2 Spike
    Pavla Taborska et al., Front Immunol, (2021)
  • T Cell–Mediated Response to SARS-CoV-2 in Liver Transplant Recipients With Prior COVID-19
    Mario Fernández-Ruiz et al., Am J Transplant, (2021)
  • Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) Study: an Observational Cohort Study of SARS-CoV-2 Infection and Vaccination in Healthcare Workers
    Jackson, B.M. et al., BMC Infect Dis, (2021)
  • Cellular Immunity Predominates Over Humoral Immunity After Homologous and Heterologous mRNA and Vector-Based COVID-19 Vaccine Regimens in Solid Organ Transplant Recipients
    Tina Schmidt et al., Am J Translplant, (2021)
  • The Legacy of Maternal SARS-CoV-2 Infection on the Immunology of the Neonate
    Sarah Gee et al., Nat Immunol, (2021)
  • A Single-Cycle Influenza A Virus-Based SARS-CoV-2 Vaccine Elicits Potent Immune Responses in a Mouse Model
    Surapong Koonpaew et al., Vaccines, (2021)
  • Impact of Multiple Sclerosis Disease-Modifying Therapies on SARS-CoV-2 Vaccine-Induced Antibody and T Cell Immunity
    Sabatino, J.J. et al., MedRxiv, (2021)
  • Complete Protection of Nasal and Lung Airways Against SARS-CoV-2 Challenge by Antibody Plus Th1 Dominant N- and S-Specific T-Cell Responses to Subcutaneous Prime and Thermally-Stable Oral Boost Bivalent hAd5 Vaccination in an NHP Study
    Elizabeth Gabitzsch et al., BioRxiv, (2021)
  • The Evaluation of Novel Oral Vaccines Based on Self-Amplifying RNA Lipid Nanparticles (saRNA LNPs), saRNA Transfected Lactobacillus Plantarum LNPs, and saRNA Transfected Lactobacillus Plantarum to Neutralize SARS-CoV-2 Variants Alpha and Delta
    Reza Keikha et al., Sci Rep, (2021)
  • Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge
    King R.G. et al., Vaccines, (2021)
  • T-Cell and Antibody Immunity After COVID-19 mRNA Vaccines in Healthy and Immunocompromised Subjects-An Exploratory Study
    Rakesh Sindhi et al., MedRxiv, (2021)
  • SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity
    Ji Yeun Kim et al., Am J Trop Med Hyg, (2021)
  • Implementation of Adenovirus-Mediated Pulmonary Expression of Human ACE2 in HLA Transgenic Mice Enables Establishment of a COVID-19 Murine Model for Assessment of Immune Responses to SARS-CoV-2 Infection
    Theodor Chitlaru et al., Pathogens, (2021)
  • Dynamics of Antibody Response to BNT162b2 Vaccine After Six Months: a Longitudinal Prospective Study
    Naaber, Paul et al., Lancet Reg Health Eur, (2021)
  • Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial
    Punnee Pitisuttihum et al., MedRxiv, (2021)
  • Protracted yet Coordinated Differentiation of Long-Lived SARS-CoV-2-Specific CD8+ T Cells During COVID-19 Convalescence
    Tongcui Ma et al., BioRxiv, (2021)
  • SARS-Cov-2 Spike Protein Fragment 674–685 Protects Mitochondria From Releasing Cytochrome c in Response to Apoptogenic Influence
    Olena Kalashnyk et al., Biochem Biophys Res Commun, (2021)
  • CD8+PD-L1+CXCR3+ Polyfunctional T Cell Abundances Are Associated With Survival in Critical SARS-CoV-2–Infected Patients
    Lucille Adam et al., JCI Insight, (2021)
  • Protective Antibodies Elicited by SARS-CoV-2 Spike Protein Vaccination are Boosted in the Lung After Challenge in Nonhuman Primates
    Joseph R. Francica et al., Sci Transl Med, (2021)
  • Profiling SARS-CoV-2 HLA-I Peptidome Reveals T Cell Epitopes From Out-of-Frame ORFs
    Shira Weingarten-Gabbay et al., Cell, (2021)
  • A Short Corticosteroid Course Reduces Symptoms and Immunological Alterations Underlying Long-COVID
    Alberto Utrero-Rico et al., Biomedicines, (2021)
  • COVID-19 Vaccine mRNA-1273 Elicits a Protective Immune Profile in Mice That is not Associated With Vaccine-Enhanced Disease Upon SARS-CoV-2 Challenge
    DiPiazza, A.T. et al., Immunity, (2021)
  • An Enveloped Virus-Like Particle Vaccine Expressing a Stabilized Prefusion form of the SARS-CoV-2 spike Protein Elicits Highly Potent Immunity
    Anne-Catherine Fluckiger et al., Vaccine, (2021)
  • Intranasal Plus Subcutaneous Prime Vaccination With a Dual Antigen COVID-19 Vaccine Elicits T-Cell and Antibody Responses in Mice
    Adrian Rice et al., Sci Rep, (2021)
  • Change in Symptoms and Immune Response in People with Post-Acute Sequelae of SARS-Cov-2 Infection (PASC) After SARS-Cov-2 Vaccination
    Daisy Massay et al., MedRxiv, (2021)
  • Evolution of SARS-CoV-2 Immune Responses in Nursing Home Residents Following Full Dose of the Comirnaty® COVID-19 Vaccine
    Giménez, E. et al., J Infect (2021)
  • Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera
    Vidal, S-J. et al., J Virol, (2021)
  • Preserved T-cell Response in anti-CD20 Treated Multiple Sclerosis Patients Following SARS-CoV-2 Vaccination
    Simon Faissner et al., Res Square, (2021)
  • Durable T cell responses contrast with faster antibody waning in BNT162b2-vaccinated elderly at 6 month
    Laurent Renia et al., Res Square, (2021)
  • SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses
    Joshua M. Carmen et al., Vaccines, (2021)
  • A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates
    M. Gordon Joyce et al., Science Translational Medicine
  • SARS-CoV-2-Specific Cell-Mediated Immunity in Kidney Transplant Recipients Recovered From COVID-19
    Mario Fernández-Ruiz et al., Transplantation, (2021)
  • SARS-CoV-2 Vaccination in Rituximab-Treated Patients: B Cells Promote Humoral Immune Responses in the Presence of T-Cell-Mediated Immunity
    Daniel Mrak et al., Ann Rheum Dis, (2021)
  • Comorbid Illnesses are Associated With Altered Adaptive Immune Responses to SARS-CoV-2
    Krystle Kq Yu et al., JCI Insight, (2021)
  • Longitudinal Analysis of Human Memory T-Cell Response According to the Severity of Illness up to 8 Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection
    Chang Kyung Kang et al., J Infect Dis, (2021)
  • Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance and Cognate Cross-Reactivity
    Alexander A. Lehmann et al., Front Immunology, (2021)
  • Identification of Conserved SARS-CoV-2 Spike Epitopes That Expand Public cTfh Clonotypes in Mild COVID-19 Patients
    Xiuyuan Lu et al., J Exp Med, (2021)
  • Effectiveness of ChAdOx1 nCoV-19 Vaccine Against SARS-CoV-2 Infection During the Delta (B.1.617.2) Variant Surge in India: a Test-Negative, Case-Control Study and a Mechanistic Study of Post-Vaccination Immune Responses
    Ramachandran Thiruvengadam et al., Lancet Infect Dis, (2021)
  • Acute Exercise Increases Immune Responses to SARS CoV-2 in a Previously Infected Man
    Baker, F. L. et al., Brain Behav Immun Health (2021)
  • Generation of Glucocorticoid-Resistant SARS-CoV-2 T Cells for Adoptive Cell Therapy
    Basar et al, Cell Reports (2021)
  • Peptide microarray based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development
    Holenya et a al, Eur J Immunol (2021)
  • Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine and SARS-CoV-2 Infection in Lung Transplant Recipients
    Havlin et al, Journal of Heart and Lung Transplantation (2021)
  • COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice
    García-Arriaza et al, Journal of Virology (2021)
  • Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates
    Francica et al, bioRxiv (2021)
  • Impaired Anti-SARS-CoV-2 Humoral and Cellular Immune Response Induced by Pfizer-BioNTech BNT162b2 mRNA Vaccine in Solid Organ Transplanted Patients
    Miele et al, American Journal of Transplantation (2021)
  • Therapeutic Antibodies, Targeting the SARS-CoV-2 Spike N-Terminal Domain, Protect Lethally Infected K18-hACE2 Mice
    Noy-Porat et al, iScience (2021)
  • CD8+ T Cells Specific for an Immunodominant SARS-CoV-2 Nucleocapsid Epitope Cross-React With Selective Seasonal Coronaviruses
    Lineburg et al, Immunity (2021)
  • Prime hAd5 Spike plus Nucleocapsid Vaccination Induces Ten-Fold Increases in Mean T-Cell Responses in Phase 1 Subjects that are Sustained Against Spike Variants
    Sieling et al, medRxiv (2021)
  • SARS-CoV-2 Mutations in MHC-I-Restricted Epitopes Evade CD8+ T Cell Responses
    Agerer et al, Science Immunology (2021)
  • Preclinical Evaluation of a SARS-CoV-2 mRNA Vaccine PTX-COVID19-B
    Liu et al, bioRxiv (2021)
  • A Lymph Node-Targeted Amphiphile Vaccine Induces Potent Cellular and Humoral Immunity to SARS-CoV-2
    Steinbuck et al, Sci Adv. (2021)
  • Neutralizing Monoclonal Anti-SARS-CoV-2 Antibodies Isolated from Immunized Rabbits Define Novel Vulnerable Spike-Protein Epitope
    Makdasi et al, Viruses (2021)
  • SARS-CoV-2 Spike Glycoprotein Vaccine Candidate NVX-CoV2373 Immunogenicity in Baboons and Protection in Mice
    Tian et al, Nat Commun. (2021)
  • Safety and Immunogenicity of the SARS-CoV-2 BNT162b1 mRNA Vaccine in Younger and Older Chinese Adults: a Randomized, Placebo-Controlled, Double-Blind Phase 1 Study
    Li et al, Nat Med. (2021)
  • BNT162b Vaccines Protect Rhesus Macaques From SARS-CoV-2
    Vogel et al, Nature. (2021)
  • Older Adults Lack SARS CoV-2 Cross-Reactive T Lymphocytes Directed to Human Coronaviruses OC43 and NL63
    Saletti et al, Sci Rep. (2021)
  • SARS-CoV-2 Variants of Concern Partially Escape Humoral but not T-Cell Responses in COVID-19 Convalescent Donors and Vaccinees
    Geers et al, Sci Immunol. (2021)
  • COVID-19 Immune Signatures Reveal Stable Antiviral T Cell Function Despite Declining Humoral Responses
    Bonifacius et al, Nat Commun. (2021)
  • IL-33 Expression in Response to SARS-CoV-2 Correlates With Seropositivity in COVID-19 Convalescent Individuals
    Stanczak et al, Nat Commun. (2021)
  • A Highly Specific Assay for the Detection of SARS-CoV-2-Reactive CD4 + and CD8 + T Cells in COVID-19 Patients
    Zelba et al, J Immunol. (2021)
  • SARS-CoV-2-Reactive T Cells in Healthy Donors and Patients With COVID-19
    Braun et al, Nature (2021)
  • Functional Characterization of CD4+ T Cell Receptors Crossreactive for SARS-CoV-2 and Endemic Coronaviruses
    Dykema et al, J Clin Invest. (2021)
  • A Single-Dose Live-Attenuated YF17D-Vectored SARS-CoV-2 Vaccine Candidate
    Sanchez-Felipe et al, Nature (2021)
  • SARS-CoV-2 Protein Subunit Vaccination of Mice and Rhesus Macaques Elicits Potent and Durable Neutralizing Antibody Responses
    Mandolesi et al, Cell Reports Medicine (2021)
  • SARS-CoV-2 mRNA Vaccine BNT162b2 Elicited a Robust Humoral and Cellular Response Against SARSCoV-2 Variants
    Lilleri et al, Research Square (2021)
  • SARS-CoV-2 Spike Protein Stabilized in The Closed State Induces Potent Neutralizing Responses
    Carnell et al, J Virol (2021)
  • Robust SARS-CoV-2-specific T Cell Immunity is maintained at 6 Months Following Primary Infection
    Zuo et al, Nature (2021)
  • First Report Demonstrating the Safety and Immunogenicity of the SARS-COV-2 BNT162b1 mRNA Vaccine in Younger and Older Chinese Adults: A Randomized, Placebo-Controlled, Observer-Blind Phase I Study
    Zhu et al, Research Square (2021)
  • 1IL-2 and IFN-γ are Biomarkers of SARS-CoV-2 Specific Cellular Response in Whole Blood Stimulation Assays
    Pérez-Cabezas et al, medRxiv (2020)
  • Adaptive Immune Responses to SARS-CoV-2 in Recovered Severe COVID-19 Patients
    Olea et al, medRxiv (2020)
  • Persistent Cellular Immunity to SARS-CoV-2 Infection
    Breton et al, bioRxiv (2020)
  • Deconvoluting the T cell response to SARS-CoV-2: specificity versus chance- and cognate cross-reactivity
    Lehmann et al, bioRxiv (2020)
  • BNT162b2 Induces SARS-CoV-2-Neutralising Antibodies and T cells in Humans
    Sahin et al, medRxiv (2020)
  • Convalescent Plasma Therapy for B-Cell Depleted Patients With Protracted COVID-19 Disease
    Hueso et al, Blood (2020)
  • Divergent SARS‐CoV‐2‐Specific T and B Cell Responses in Severe but Not Mild COVID‐19 Patients
    Oja et al, European Journal of Immunology (2020)
  • mRNA based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus neutralizing antibodies and mediates protection in rodents
    Rauch et al, bioRxiv (2020)
  • T Cell and Antibody Responses to SARS-CoV-2: Experience From a French Transplantation and Hemodialysis Center During the COVID-19 Pandemic
    Candon et al, Am J Transplant (2020)
  • Intrafamilial Exposure to SARS-CoV-2 Induces Cellular Immune Response without Seroconversion
    Gallais et al, Emerg Infect Dis (2020)
  • A Glimpse Into the Diverse Cellular Immunity Against SARS-CoV-2
    Chang et al, Research Square (2020)
  • Immunogenicity of novel mRNA COVID-19 vaccine MRT5500 in mice and 2 non-human primates
    Kalnin et al, bioRxiv (2020)
  • Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in Older Adults
    Anderson et al, NEJM (2020)
  • Divergent SARS-CoV-2-specific T and B cell Responses in Severe but Not Mild COVID-19
    Oja et al, bioRxiv (2020)
  • Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
    Corbett et al, New England J of Med (2020)
  • Presence of SARS-CoV-2 reactive T cells in COVID-19 Patients and Healthy Donors
    Braun et al, Nature (2020)
  • Single-shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques
    Mercado et al, Nature (2020)
  • SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness
    Corbett et al, bioRxiv (2020)
  • Data, Reagents, Assays and Merits of Proteomics for SARS-CoV-2 Research and Testing
    Zecha et al, Mol Cell Proteomics (2020)
  • A Longitudinal Study of Immune Cells in Severe COVID-19 Patients
    Payen et al, medRXiv (2020)
  • SARS-CoV-2-Specific T cells Exhibit Unique Features Characterized by Robust Helper Function, Lack of Terminal Differentiation, and High Proliferative Potential
    Neidleman et al, bioRxiv (2020)
  • Generation of SARS-CoV-2 S1 Spike Glycoprotein Putative Antigenic Epitopes in vitro by Intracellular Aminopeptidases
    Stamatakis et al bioRxiv (2020)
  • Self-Amplifying RNA SARS-CoV-2 Lipid Nanoparticle Vaccine Candidate Induces High Neutralizing Antibody Titers in Mice
    McKay et al, Nature (2020)
  • An mRNA Vaccine Against SARS-CoV-2 — Preliminary Report
    Jackson et al, New England J of Med (2020)
  • SARS‐CoV‐2‐Reactive Interferon‐γ‐producing CD8+ T cells in Patients Hospitalized with Coronavirus Disease 2019
    Giminez et al, J Med Vir (2020)
  • Concurrent Human Antibody and TH1 type T-cell Responses 2 Elicited by a COVID-19 RNA Vaccine
    Sahin et al, medRXiv (2020)
Application Notes
Loading...

Check our list of products, click and go.

Get a quote